# Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis

> **NCT00833079** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 500 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tacrolimus 0.1% manufactured by Taro
- **DRUG:** Protopic - Tacrolimus 0.1%
- **DRUG:** Tacrolimus Vehicle manufactured by Taro

## Key facts

- **NCT ID:** NCT00833079
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-03
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833079, "Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00833079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*